Jun 25,2021

ABBOTT HOSTS CONFERENCE CALL FOR SECOND-QUARTER EARNINGS

Abbott will announce its second-quarter 2021 financial results on Thursday, July 22, 2021, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 25,2021

LATE-BREAKING DATA DEMONSTRATE ABBOTT'S FREESTYLE® LIBRE SYSTEM SUPPORTS HEALTH EQUITY FOR MILLIONS OF AMERICANS LIVING WITH DIABETES

Comparative data presented at the American Diabetes Association J19 Scientific Sessions show Abbott's diabetes technology delivers the same reductions of HbA1c and acute complications(1,2) as the competitor systems while reaching a much wider, more diverse population

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 26,2021

Insulet’s Omnipod® 5 Automated Insulin Delivery System Pivotal Studies Demonstrate Improved Outcomes Across the Lifespan from Ages 2 to 70 years

Omnipod 5, the world’s first tubeless, wearable automated insulin delivery (AID) system that continuously adapts insulin delivery based on glucose levels and trends, significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 years with type 1 diabetes. These pivotal study data from the preschool age group were presented at the American Diabetes Association (ADA) Virtual 81st Scientific Sessions.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 27,2021

Tandem Diabetes Care Announces Presentations Demonstrating Positive Real-World Improvements with Control-IQ Technology Across Diverse Populations

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, today presented positive real-world data from ongoing use of the t:slim X2™ insulin pump with Control-IQ® advanced hybrid closed-loop technology, demonstrating statistically significant improvements in glycemic and patient-reported outcomes. Emphasis was placed on qualitative experiences as well as insights from diverse populations using the system. The data was presented this week during the 81st Scientific Sessions of the American Diabetes Association.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 28,2021

Medtronic InPen™ Real-World Data and Extended Infusion Set* Pivotal Trial Results Demonstrate Strong Clinical Outcomes and Positive User Experience

Medtronic plc, today announced key clinical data from the virtual 81st annual American Diabetes Association Scientific Sessions. The presentations illustrated increases in Time in Range when using an InPen™ smart insulin pen, safety of an extended-wear infusion set that lasts up to 7 days, and patient satisfaction with the longer-wear infusion set.

PRODUCT

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jun 30,2021

Nemaura Medical Reports Results and Provides Business Update for the Fiscal Year Ended March 31, 2021

Nemaura Medical Inc., a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT™diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a business update and released financial results for the fiscal year ended March 31, 2021.

View Analyst & Ambassador Comments
Go to original news
Jun 30,2021

Nemaura Medical Announces Presentation on its Licensed Why WAIT Program During the American Diabetes Association 81st Annual Scientific Sessions

Nemaura Medical, Inc., a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces a presentation referring to its licensed Why WAIT® program at the American Diabetes Association’s 81st Annual Scientific Sessions.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 30,2021

BD To Announce Financial Results For Its Third Quarter Of Fiscal 2021

BD announced today that it will report its financial results for the third quarter of fiscal year 2021 on Thursday, August 5, 2021. BD will issue a press release detailing the quarter's results, along with related presentation materials posted to www.bd.com/investors, at approximately 6:00 a.m. Eastern Time (ET).

View Analyst & Ambassador Comments
Go to original news
Jul 15,2021

Rimidi Enhances Leading Clinical Management Platform To Meet the New Needs of Hospitals and Health Systems

Created for clinicians by clinicians, Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, today announced enhancements to its EHR-integrated platform designed to better support hospitals and health systems as they seek to overcome many challenges identified prior to -- and during -- the COVID-19 pandemic.

View Analyst & Ambassador Comments
Go to original news
Jul 01,2021

MyWay Digital Health wins government funding for its innovative technology

MyWay Digital Health was one of 15 organisations to receive the funding (subject to contract), which was announced by Department of Health and Social Care (DHSC) on 16 June 2021. The AI Award is making £140 million available over four years to accelerate the testing and evaluation of artificial intelligence technologies which meet the aims set out in the NHS Long Term Plan.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES